HKSecWiki新股资讯 2021年12月21日
12:36 AM EST, 12/20/2021 (MT Newswires) -- US-based Sirnaomics (HKG:2257) on Monday launched its initial public offering in Hong Kong that seeks to raise as much as HK$548.2 million ($70.3 million).
The Maryland-headquartered biopharmaceutical company, which also has a presence in China, is offering 7.54 million shares at HK$65.90 to HK$72.70 each. Of the total number of shares on offer, 754,000 shares are allotted for Hong Kong investors.
The issuer expects to determine the offer price on Dec. 23 and disclose the allocations on Dec. 29. It intends to start trading on the Hong Kong bourse on Dec. 30, according to a Monday filing.
Two cornerstone investors committed to subscribe for $29 million worth of IPO shares.
Listing proceeds will be used to fund the clinical trials, research, development and commercialization of drug candidates and other products in the pipeline, as well as for working capital.
CICC, HSBC, Nomura, China Merchants Securities, China PA Securities, Alpha Win Capital and Valuable Capital are the joint bookrunners and global coordinators of the deal.
免责声明：中文翻译由腾讯翻译君提供支持，富途对翻译信息的准确性或可靠性所造成的任何损失不承担任何责任。
Was this helpful?
0 / 0
本文链接： https://www.hksecwiki.com/news/p11764641/
由HKSecWiki香港券商百科整理发布，香港证券开户请访问hksecwiki.com